{
  "id": "glp1_agonist_education_selectAll_v1",
  "type": "selectAll",
  "stem": "The nurse is providing education for a client starting a GLP-1 receptor agonist (e.g., semaglutide) for type 2 diabetes and weight management. Which information should the nurse include in the teaching?",
  "options": [
    {
      "id": "a",
      "text": "Report any new or worsening depression or suicidal thoughts immediately."
    },
    {
      "id": "b",
      "text": "Administer the injection once daily at the same time each day."
    },
    {
      "id": "c",
      "text": "Expect mild nausea and decreased appetite during the first few weeks."
    },
    {
      "id": "d",
      "text": "Contact the healthcare provider for severe, persistent abdominal pain."
    },
    {
      "id": "e",
      "text": "Discontinue the medication if you experience a single episode of vomiting."
    },
    {
      "id": "f",
      "text": "Rotate the injection site among the abdomen, thigh, or upper arm."
    }
  ],
  "correctOptionIds": [
    "a",
    "c",
    "d",
    "f"
  ],
  "scoring": {
    "method": "polytomous",
    "maxPoints": 4
  },
  "pedagogy": {
    "bloomLevel": "apply",
    "cjmmStep": "takeAction",
    "nclexCategory": "Pharmacological and Parenteral Therapies",
    "difficulty": 3,
    "topicTags": [
      "Pharmacology",
      "Endocrine",
      "Client Education",
      "GLP-1 Agonist",
      "Semaglutide",
      "Type 2 Diabetes",
      "Weight Management",
      "Medication Administration",
      "Adverse Effects"
    ]
  },
  "answerBreakdown": {
    "a": {
      "correct": true,
      "rationale": "GLP-1 receptor agonists can affect the central nervous system and may lead to changes in mood, including depression and suicidal thoughts. Prompt reporting allows for timely intervention and management.",
      "content": "Correct. Reporting new or worsening depression or suicidal thoughts is crucial due to potential CNS effects of the medication."
    },
    "b": {
      "correct": false,
      "rationale": "Semaglutide is typically administered once weekly, not daily. Daily administration could lead to an overdose and increased risk of side effects.",
      "content": "Incorrect. Semaglutide is usually administered once weekly."
    },
    "c": {
      "correct": true,
      "rationale": "Nausea and decreased appetite are common side effects, especially during the initial weeks of treatment, as the body adjusts to the medication's effects on gastric emptying and satiety.",
      "content": "Correct. Mild nausea and decreased appetite are expected side effects during the first few weeks."
    },
    "d": {
      "correct": true,
      "rationale": "Severe, persistent abdominal pain can be a sign of pancreatitis, a rare but serious adverse effect of GLP-1 receptor agonists. Prompt medical evaluation is necessary.",
      "content": "Correct. Severe abdominal pain could indicate pancreatitis and requires immediate medical attention."
    },
    "e": {
      "correct": false,
      "rationale": "A single episode of vomiting is not necessarily a reason to discontinue the medication. However, persistent or severe vomiting should be reported to the healthcare provider.",
      "content": "Incorrect. A single episode of vomiting does not warrant discontinuation of the medication, but persistent vomiting should be reported."
    },
    "f": {
      "correct": true,
      "rationale": "Rotating injection sites helps prevent lipohypertrophy (thickening of the subcutaneous fat) and ensures consistent absorption of the medication.",
      "content": "Correct. Rotating injection sites prevents lipohypertrophy and ensures consistent medication absorption."
    }
  },
  "questionTrap": "The question traps include confusing common side effects with serious adverse effects and misunderstanding the frequency of administration for semaglutide.",
  "mnemonics": "Consider the mnemonic 'GEMS' for GLP-1 agonist education:\n- G: GI upset (nausea, appetite changes)\n- E: Emotional changes (depression, suicidal thoughts)\n- M: Monitor for pancreatitis (abdominal pain)\n- S: Site rotation (for injections)",
  "sbar": {
    "situation": "The client is starting a GLP-1 receptor agonist (e.g., semaglutide) for type 2 diabetes and weight management.",
    "background": "The client has type 2 diabetes and requires education on the new medication, including administration, expected side effects, and potential complications.",
    "assessment": "The client's understanding of diabetes management and medication administration is being assessed. The client needs education on GLP-1 receptor agonists.",
    "recommendation": "Provide comprehensive education on GLP-1 receptor agonist therapy, including administration technique, side effect management, and when to contact the healthcare provider."
  },
  "clinicalPearls": [
    "Start with a low dose of the GLP-1 agonist and gradually increase as tolerated to minimize gastrointestinal side effects.",
    "Educate clients on the importance of proper injection technique and site rotation.",
    "Monitor clients for signs and symptoms of pancreatitis.",
    "Advise clients to report any new or worsening depression or suicidal thoughts.",
    "Review the client's medication list for potential interactions."
  ],
  "sentinelStatus": "healed_v2026_v11",
  "rationale": {
    "correct": "The correct options highlight essential information for a client starting a GLP-1 receptor agonist, including potential adverse effects (depression, pancreatitis) and proper administration techniques (site rotation) and expected side effects (nausea). The incorrect options present inaccurate information regarding administration frequency and management of common side effects."
  }
}